Just now, a Nobel Prize winner has joined Anthropic as a new employee!

Some netizens remarked, 'Anthropic has welcomed a Nobel laureate—top talent continues to concentrate at OpenAI and Anthropic.' Others exclaimed outright: 'First Karpathy, now the mind behind AlphaFold—Anthropic is assembling an AI Avengers team.' Logan Kilpatrick jokingly expressed anticipation that Jumper would 'win another Nobel Prize.' Though tongue-in-cheek, it’s not entirely hyperbolic upon reflection. After the initial shock, everyone asked the same question—what exactly happened at Google? Jumper didn’t say. Anthropic didn’t say. Neither did Google. Perhaps investor Lior Alexander’s comment comes closest to an answer: 'Cutting-edge AI labs are selling something Google can’t offer: the feeling that one person can change the trajectory of a company.' A $2.7 billion acquisition—and still couldn’t retain him Just two days before Jumper’s official announcement, Noam Shazeer announced his departure from Google to join OpenAI as 'Head of Architecture Research.' He was a core author of the 2017 landmark paper 'Attention Is All You Need'—the foundation of modern AI. He designed multi-head attention and wrote, line by line, the first working implementation that surpassed state-of-the-art benchmarks. To lure him back from Character.AI, Google paid $2.7 billion. Upon returning, Shazeer became co-lead of Gemini—the flagship model driving Google’s large-language-model counteroffensive. Yet less than two years later, he left. Two days after that, Jumper also departed. They were neither the first nor will be the last. Over the past eight years, more than 20 top researchers—co-authors on milestone papers—have successively left DeepMind/Google Brain. In 2025 alone, at least 11 executives resigned. Even Mustafa Suleyman, DeepMind’s co-founder, was poached by Microsoft in a $650 million acqui-hire. Life sciences: the next battlefield for AI’s 'Big Three' Back at Anthropic, the groundwork had already begun over two months earlier. On April 3, Anthropic acquired biotech startup Coefficient Bio for $400 million in stock. With fewer than ten employees, the team had already produced industry-leading results in AI-driven antibody design. Meanwhile, Anthropic has been building its own wet lab; last October, it launched Claude for Life Sciences—a tool helping researchers accelerate drug discovery and experimental design—and in January rolled out Claude for Healthcare, tailored for medical institutions. Its stated goal: compress the life-sciences R&D cycle by tenfold. Now, a Nobel-caliber protein scientist has been brought in to lead this effort. In fact, Anthropic isn’t the only one betting big on life sciences.

Anthropic quietly built a biology lab! Claude directs robots to conduct experiments—AI-powered drug discovery advances further.

Anthropic is extending its artificial intelligence ambitions further into real-world biology. This ChatGPT competitor has established a physical biology laboratory in the San Francisco Bay Area and recruited specialists in biochemistry—signaling that its life-sciences strategy is shifting from computational simulation to hands-on experimentation. On September 18, according to Reuters, two informed sources revealed that Anthropic has begun constructing a physical lab and is actively hiring talent in biochemistry. Eric Kauderer-Abrams, Anthropic’s Head of Life Sciences, confirmed the lab’s existence, stating, 'The ultimate test of biology—now and always—remains real laboratory work.' This move comes at an especially sensitive time for Anthropic. Over the past two weeks, its researchers have warned that AI could lead to human extinction, and the company itself disclosed cases where its systems had been used for biological weapons development. Meanwhile, Anthropic is preparing for an IPO potentially valued at up to $2 trillion—and life sciences has become one of its largest strategic investments in terms of personnel and resources. Kauderer-Abrams called it 'the single greatest opportunity yet to fulfill our mission.' From computational simulation to real-world experimentation Establishing a physical biology lab—commonly known as a 'wet lab'—means Anthropic is now moving beyond AI-generated biological predictions and screenings in silico, and beginning to validate those findings through actual experiments. Kauderer-Abrams explained that the company will adopt a biotech-style operational model: conducting some experiments in-house while partnering externally for others. Anthropic clarified that the lab is not dedicated solely to drug development, though it declined to share further details. Recent job postings include roles such as Procurement & Operations Lead, and Protein and Nucleic Acid Characterization Specialist—with one listing explicitly aiming to 'accelerate life-science progress by an order of magnitude.' Kauderer-Abrams emphasized that building an in-house lab is about speed: 'Some things can be done much faster when they’re under our direct control,' and expressed hopes to eventually 'operate at the largest possible scale.' Acquisitions and partnerships expand life-sciences capabilities Anthropic is also bolstering its life-sciences capabilities through acquisitions, software products, and collaborations with pharmaceutical companies. Reports indicate the company acquired startup Coefficient Bio for approximately $400 million in stock—intending to leverage it as a cornerstone for building drug-discovery tools. The company has also launched Claude Science and, in June, announced plans to independently run drug-development projects—focusing specifically on preclinical research areas where traditional pharma companies invest little due to perceived insufficient returns.

Anthropic Quietly Sets Up Biology Lab as It Ramps AI Drug Program

3 days ago

Anthropic established a physical biology lab to advance AI-driven drug discovery, partnering with major pharma firms like Novartis and Roche. The company acquired Coefficient Bio to accelerate development of treatments for rare diseases.

reuters

2026-09-11

Anthropic Says It Blocked AI Misuse That Could Support Biological Weapons

2026-09-18

Anthropic Quietly Sets Up Biology Lab as It Ramps AI Drug Program

Anthropic Quietly Sets Up Biology Lab as It Ramps AI Drug Program

FAQ